Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Restart Life Sciences (HN30) AI Stock Analysis

DE:HN30

Restart Life Sciences

(Frankfurt:HN30)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Balance-sheet recoveryPositive equity in 2025 and modest leverage provide a stronger financial base than the preceding years. This improvement may support financing flexibility and reduce immediate balance-sheet pressure, although the benefit remains tempered by the company’s prior equity instability.
Negative Factors
No recurring revenueThe absence of recurring revenue leaves the business without a demonstrated commercial engine and makes operating losses difficult to absorb. Until revenue begins to scale consistently, the company’s ability to fund growth internally and establish durable earnings power remains very limited.

Restart Life Sciences (HN30) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%DE:HN30-22.64%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 519.02K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-2.0
Beta (1Y)
0.86
Revenue Growth
―
EPS Growth
-457.14%
Country
Germany
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Restart Life Sciences Business Overview & Revenue Model

Company Description

Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder,...

Restart Life Sciences Peers Comparison

Overall Rating

Financial Indicators

DE:HN30 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:HN30TSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:HN30 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:HN30Restart Life Sciences Corp.0.04-0.01-22.64%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.10-1.90-94.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.